Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Chia

Showing results (241-250 of 256) with videos related to

Pageof 26
Sort By:
Palliative Care and Social Practice|October 22, 2025
Palliative care in surgery: Where are we at?Darryl W K Juan, Yang Yann Foo, Natalie H Soh, et al.
The Pharmacogenomics Journal|May 28, 2014
Pharmacogenomic diversity in Singaporean populations and EuropeansL R Brunham, S L Chan, R Li, et al.
ESMO Open|November 30, 2025
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survivalJ Crown, D Stroyakovskii, D A Yardley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2025
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapyE L Mayer, F-C Bidard, Y H Park, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancerM R Jones, H Lim, Y Shen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2024
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trialG N Hortobagyi, A Lacko, J Sohn, et al.
Environment International|June 13, 2024
Long-term exposure to particulate matter and all-cause and cause-specific mortality in an analysis of multiple Asian cohortsG S Downward, P Hystad, S Tasmin, et al.
Frontiers in Oncology|June 28, 2024
Transcriptomic convergence despite genomic divergence drive field cancerization in synchronous squamous tumorsQiu Xuan Tan, Nicholas B Shannon, Weng Khong Lim, et al.
ACS Medicinal Chemistry Letters|August 16, 2019
Correction to "Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3"Chuhui Huang, Si Si Liew, Grace R Lin, et al.
ACS Medicinal Chemistry Letters|June 22, 2019
Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3Chuhui Huang, Si Si Liew, Grace R Lin, et al.
Pageof 26

Showing results (241-250 of 256) with videos related to

Sort By:
Pageof 26
Palliative Care and Social Practice|October 22, 2025
Palliative care in surgery: Where are we at?Darryl W K Juan, Yang Yann Foo, Natalie H Soh, et al.
The Pharmacogenomics Journal|May 28, 2014
Pharmacogenomic diversity in Singaporean populations and EuropeansL R Brunham, S L Chan, R Li, et al.
ESMO Open|November 30, 2025
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survivalJ Crown, D Stroyakovskii, D A Yardley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2025
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapyE L Mayer, F-C Bidard, Y H Park, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancerM R Jones, H Lim, Y Shen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2024
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trialG N Hortobagyi, A Lacko, J Sohn, et al.
Environment International|June 13, 2024
Long-term exposure to particulate matter and all-cause and cause-specific mortality in an analysis of multiple Asian cohortsG S Downward, P Hystad, S Tasmin, et al.
Frontiers in Oncology|June 28, 2024
Transcriptomic convergence despite genomic divergence drive field cancerization in synchronous squamous tumorsQiu Xuan Tan, Nicholas B Shannon, Weng Khong Lim, et al.
ACS Medicinal Chemistry Letters|August 16, 2019
Correction to "Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3"Chuhui Huang, Si Si Liew, Grace R Lin, et al.
ACS Medicinal Chemistry Letters|June 22, 2019
Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3Chuhui Huang, Si Si Liew, Grace R Lin, et al.
Pageof 26